Famous fund manager's second quarter repositioning plan exposed: Increase holdings in military industry, differences in pharmaceutical sector.

Recently, with some listed companies disclosing the top ten largest shareholders, the trading trends of some well-known fund managers in the first half of the year have been exposed. Journalists found that currently, there are still disagreements among fund managers regarding pharmaceutical stocks. For example, in the second quarter, while Dongfang Biology, which was increased by Wan Minyuan, some fund managers chose to reduce their holdings; and Maoweibio, a long-term holding of Jin Xiao Fei, was reduced by Lu Bin. Interviewees pointed out that the disagreements in the market regarding the pharmaceutical sector mainly focus on valuation and performance realization, innovation drug research and development risks and returns, market sentiment and fund flows, policy impact, and short-term volatility. In addition, recently, public funds have shown increased interest in the defense industry sector. Some institutions have warned that the defense industry sector is trading hot and attention should be paid to short-term volatility risks.